Lv3
330 积分 2024-03-05 加入
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease
1个月前
已完结
Beyond Randomized Clinical Trials: Use of External Controls
2个月前
已完结
Long-Term Stapokibart Treatment Induces Sustained Clinical Improvements in Patients With Moderate-to-Severe Atopic Dermatitis
4个月前
已完结
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial
5个月前
已完结
Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 3 trial
5个月前
已完结
Long-term efficacy and safety of stapokibart for moderate-to-severe atopic dermatitis: 52-week results from a phase 3 trial
5个月前
已完结
Diagnostic Features of Atopic Dermatitis
8个月前
已完结
First-in-Human Study of REGN668/SAR231893 (IL-4Rα mAb): Safety, Tolerability and Biomarker Results of a Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study in Healthy Volunteers
8个月前
已完结
皖公网安备34019202002308
